Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

APLM

Apollomics Inc

Jan 14 • 04:00PM ET

10.12

Dollar change -0.73
Percentage change -6.69	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN AMGN VRTX BIIB INCY BMRN NBIX EXEL BLUE

| Held by: CNCR CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	38.34%	Shs Outstand	10.84M	Perf Week	-9.64%
Market Cap	11.16M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.68M	Perf Month	31.43%
Income	-57.11M	PEG	-	EPS next Q	-	Inst Own	2.06%	Short Float	1.58%	Perf Quarter	-27.71%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-77.30%	Short Ratio	0.03	Perf Half Y	-49.02%
Book/sh	0.19	P/B	53.49	EPS next Y	-	ROA	-107.81%	Short Interest	0.01M	Perf Year	-89.55%
Cash/sh	23.51	P/C	0.43	EPS next 5Y	-	ROE	-149.31%	52W Range	6.50 - 105.00	Perf YTD	3.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-98.14%	ROI	-262.49%	52W High	-90.36%	Beta	0.98
Dividend TTM	-	Quick Ratio	2.25	Sales past 5Y	0.00%	Gross Margin	-	52W Low	55.69%	ATR (14)	1.41
Dividend Ex-Date	-	Current Ratio	2.25	EPS Y/Y TTM	-911.91%	Oper. Margin	-	RSI (14)	49.61	Volatility	8.98% 13.67%
Employees	-	Debt/Eq	0.23	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	400.00
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-1366.67%	Payout	-	Rel Volume	0.03	Prev Close	10.85
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	324.06K	Price	10.12
SMA20	2.59%	SMA50	-3.07%	SMA200	-52.69%	Trades		Volume	8,895	Change	-6.69%

Dec-20-24 08:00AM	Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Dec-10-24 04:05PM	Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -14.25% +7.54%
Nov-21-24 08:00AM	Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split (GlobeNewswire) -32.58%
Sep-16-24 08:00AM	Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-04-24 04:05PM	Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +5.13% +5.89%
06:00AM	Loading…
Aug-14-24 06:00AM	Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress (GlobeNewswire)
Aug-13-24 08:00AM	Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial (GlobeNewswire) -11.24%
Aug-08-24 04:05PM	Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Jul-16-24 04:47PM	Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +12.82%
Jul-03-24 08:45AM	Apollomics execs lead job cuts as cancer biotech ekes out cash (FierceBiotech.com)
08:00AM	Apollomics Announces Updated Strategic Focus and Leadership Team Changes (GlobeNewswire)
Jun-04-24 08:00AM	Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -8.16%
May-29-24 08:00AM	Apollomics Announces Presentation at the 2024 BIO International Convention (GlobeNewswire) +14.66%
May-08-24 04:05PM	Apollomics Announces Private Placement Financing and Addition to Board of Directors (GlobeNewswire)
Apr-25-24 08:30AM	Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene (GlobeNewswire)
07:00AM	Loading…
Apr-10-24 07:00AM	Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-02-24 08:00AM	Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -7.93%
Mar-28-24 07:00AM	Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results (GlobeNewswire) +23.97%
Mar-26-24 08:00AM	Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024 (GlobeNewswire)
Mar-04-24 10:18AM	Apollomics Names Matthew Plunkett as Chief Financial Officer (Exec Edge)
07:00AM	Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer (GlobeNewswire)
Feb-07-24 07:00AM	Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +13.33%
Jan-19-24 04:15PM	Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Jan-17-24 04:30PM	Apollomics to Participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference (GlobeNewswire)
Jan-03-24 06:52PM	Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment (Exec Edge) -10.05%
07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire)
Jan-02-24 04:30PM	Apollomics to Present at the 2024 Biotech Showcase (GlobeNewswire)
Dec-07-23 01:01PM	Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication (Exec Edge) -8.14%
Dec-04-23 07:00AM	Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation (GlobeNewswire) -15.12%
Nov-29-23 07:30AM	Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference (GlobeNewswire)
07:00AM	Loading…
Nov-28-23 07:00AM	Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC) (GlobeNewswire)
Nov-16-23 08:30AM	Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-31-23 08:30AM	Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation (GlobeNewswire) -11.11%
Oct-27-23 08:03AM	Why Is Apollomics (APLM) Stock Up 113% Today? (InvestorPlace) +51.76%
Oct-26-23 08:50AM	Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion (GlobeNewswire) -26.23%
Oct-24-23 09:35AM	Apollomics Treating MET-Altered Cancers: KUNPENG Trial Results (Exec Edge) -5.37%
Oct-23-23 08:30AM	Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% (GlobeNewswire) -43.24%
Oct-16-23 06:55PM	Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 (GlobeNewswire)
Sep-28-23 04:17PM	Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-06-23 07:00AM	Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Apr-11-23 08:30AM	Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium (GlobeNewswire) -14.00%
Mar-31-23 08:01AM	Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq (PR Newswire) -17.69%
Mar-30-23 08:00AM	Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq (GlobeNewswire) +171.97%
07:30AM	Apollomics Co-Founder & CEO Guo-Liang Yu on Treating Cancer, Going Public (IPO-Edge.com)

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLM

Apollomics Inc

Upgrade your FINVIZ experience